Rebecca E. Mercer

759 total citations
20 papers, 496 citations indexed

About

Rebecca E. Mercer is a scholar working on Economics and Econometrics, Oncology and Immunology. According to data from OpenAlex, Rebecca E. Mercer has authored 20 papers receiving a total of 496 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Economics and Econometrics, 6 papers in Oncology and 5 papers in Immunology. Recurrent topics in Rebecca E. Mercer's work include Health Systems, Economic Evaluations, Quality of Life (11 papers), Economic and Financial Impacts of Cancer (7 papers) and Biosimilars and Bioanalytical Methods (5 papers). Rebecca E. Mercer is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (11 papers), Economic and Financial Impacts of Cancer (7 papers) and Biosimilars and Bioanalytical Methods (5 papers). Rebecca E. Mercer collaborates with scholars based in Canada, United States and United Kingdom. Rebecca E. Mercer's co-authors include Rachel Wevrick, William F. Colmers, Melissa J. Chee, Matthijs van Eede, R. Mark Henkelman, Jocelyn M. Bischof, Kelvin Chan, Wei Fang Dai, Jaclyn Beca and Wanrudee Isaranuwatchai and has published in prestigious journals such as PLoS ONE, The Lancet Oncology and International Journal of Cancer.

In The Last Decade

Rebecca E. Mercer

17 papers receiving 483 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rebecca E. Mercer Canada 8 172 148 121 67 61 20 496
Annalisa Buniello United Kingdom 14 360 2.1× 374 2.5× 13 0.1× 18 0.3× 32 0.5× 20 920
Aaron Osborne United States 21 58 0.3× 300 2.0× 32 0.3× 11 0.2× 37 0.6× 37 1.7k
Kristin L. Ayers United States 11 300 1.7× 167 1.1× 47 0.4× 5 0.1× 24 0.4× 22 610
Tohru Noguchi Japan 18 58 0.3× 134 0.9× 28 0.2× 32 0.5× 25 0.4× 37 790
Jennie Larkin United States 14 67 0.4× 403 2.7× 196 1.6× 10 0.1× 50 0.8× 19 925
Tianzhou Ma United States 10 60 0.3× 235 1.6× 148 1.2× 4 0.1× 52 0.9× 49 605
Shihong Mao United States 13 219 1.3× 358 2.4× 10 0.1× 7 0.1× 86 1.4× 25 760
Frank W. Pun Hong Kong 17 178 1.0× 427 2.9× 8 0.1× 9 0.1× 93 1.5× 38 817
Samuel P. Dickson United States 10 623 3.6× 374 2.5× 14 0.1× 13 0.2× 25 0.4× 29 1.0k
Mingyu Gu China 16 54 0.3× 642 4.3× 109 0.9× 4 0.1× 165 2.7× 42 1.1k

Countries citing papers authored by Rebecca E. Mercer

Since Specialization
Citations

This map shows the geographic impact of Rebecca E. Mercer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebecca E. Mercer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebecca E. Mercer more than expected).

Fields of papers citing papers by Rebecca E. Mercer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rebecca E. Mercer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebecca E. Mercer. The network helps show where Rebecca E. Mercer may publish in the future.

Co-authorship network of co-authors of Rebecca E. Mercer

This figure shows the co-authorship network connecting the top 25 collaborators of Rebecca E. Mercer. A scholar is included among the top collaborators of Rebecca E. Mercer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebecca E. Mercer. Rebecca E. Mercer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Paggio, Joseph C. Del, Scott Gavura, Rebecca E. Mercer, et al.. (2024). Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study. The Lancet Oncology. 25(4). 431–438. 8 indexed citations
3.
4.
Beca, Jaclyn, et al.. (2024). Comparative Safety and Effectiveness of Bevacizumab Biosimilars to Originator for the Treatment of Metastatic Colorectal Cancer. Journal of the National Comprehensive Cancer Network. 22(10). 677–684. 1 indexed citations
5.
Dai, Wei Fang, Ruth Croxford, Wanrudee Isaranuwatchai, et al.. (2023). Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization. Cancer Medicine. 12(10). 11451–11461. 3 indexed citations
6.
7.
Dai, Wei Fang, Jaclyn Beca, Chenthila Nagamuthu, et al.. (2022). Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer. JAMA Network Open. 5(2). e2145460–e2145460. 6 indexed citations
8.
9.
Mercer, Rebecca E., et al.. (2021). Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario. Current Oncology. 28(2). 1056–1066.
10.
Dai, Wei Fang, Maureen Trudeau, Rebecca E. Mercer, et al.. (2020). Impact of rarity on Canadian oncology health technology assessment and funding. International Journal of Technology Assessment in Health Care. 36(4). 404–409. 4 indexed citations
11.
Mercer, Rebecca E., et al.. (2020). Are We Making a Difference? A Qualitative Study of Patient Engagement at the pan-Canadian Oncology Drug Review: Perspectives of Patient Groups. Value in Health. 23(9). 1157–1162. 7 indexed citations
12.
Clausen, Marc, Chloe Mighton, Wei Fang Dai, et al.. (2020). Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders’ perspectives. CMAJ Open. 8(4). E772–E778. 7 indexed citations
13.
Chan, Kelvin, Claire de Oliveira, Scott Gavura, et al.. (2020). Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration. BMJ Open. 10(1). e032884–e032884. 38 indexed citations
14.
Dai, Wei Fang, Jaclyn Beca, Ruth Croxford, et al.. (2020). Real‐world, population‐based cohort study of toxicity and resource utilization of second‐line ipilimumab for metastatic melanoma in Ontario, Canada. International Journal of Cancer. 148(8). 1910–1918. 7 indexed citations
15.
Mercer, Rebecca E., et al.. (2013). Magel2 Is Required for Leptin-Mediated Depolarization of POMC Neurons in the Hypothalamic Arcuate Nucleus in Mice. PLoS Genetics. 9(1). e1003207–e1003207. 56 indexed citations
16.
Mercer, Rebecca E., Melissa J. Chee, & William F. Colmers. (2011). The role of NPY in hypothalamic mediated food intake. Frontiers in Neuroendocrinology. 32(4). 398–415. 145 indexed citations
17.
Mercer, Rebecca E. & Rachel Wevrick. (2009). Loss of Magel2, a Candidate Gene for Features of Prader-Willi Syndrome, Impairs Reproductive Function in Mice. PLoS ONE. 4(1). e4291–e4291. 74 indexed citations
18.
Mercer, Rebecca E., et al.. (2009). Regionally reduced brain volume, altered serotonin neurochemistry, and abnormal behavior in mice null for the circadian rhythm output gene Magel2. American Journal of Medical Genetics Part B Neuropsychiatric Genetics. 150B(8). 1085–1099. 78 indexed citations
19.
Windsor, Russell E. & Rebecca E. Mercer. (1979). Suspected acute myopathy of pigs. Veterinary Record. 105(12). 276–278. 2 indexed citations
20.
Mercer, Rebecca E., et al.. (1978). ADAPTIVE SEARCH USING A REPRODUCTIVE META‐PLAN. Kybernetes. 7(3). 215–228. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annalisa Buniello Breakdown of academic impact, for papers by Aaron Osborne Breakdown of academic impact, for papers by Kristin L. Ayers Breakdown of academic impact, for papers by Tohru Noguchi Breakdown of academic impact, for papers by Jennie Larkin Breakdown of academic impact, for papers by Tianzhou Ma Breakdown of academic impact, for papers by Shihong Mao Breakdown of academic impact, for papers by Frank W. Pun Breakdown of academic impact, for papers by Samuel P. Dickson Breakdown of academic impact, for papers by Mingyu Gu
Rankless by CCL
2026